Company announcements · 04/11/20261 min read

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

Summary

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertip (MEN1703), a first-in-class oral dual PIM/ FLT3 kinase inhibitor, in patients with relapsed/ refractory...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Related companies

WITH
Open profile →Explore businesses on Business Maps →

Explore insights

Business insights →

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

Zhejiang Wenda Pharma announces positive results from Phase II trial of NHWD-870 HCl oral BET inhibitor at the 2026 ESMO Annual Meeting

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First Line Non-Small Cell Lung Cancer at ESMO 2026

Chemomab Therapeutics and Scipher Medicine announce SEC Registration Statement on Form S-4 is effective

First Hawaiian, Inc. and TriCo Bancshares announce shareholder approvals of acquisition

Landis+Gyr announces financial results for the second quarter and first half of 2026

Boots Group Finco L.P. and The Boots group Luxco S.à r.l. announce the expiry and results of the consent request for their €650,000,000 5.375% Senior Secured Notes due in 2032 and £375,000,000 7.375% senior secured Nots due in 2032.